beta-Thalassemia

This is a blood disorder where the body doesn't make enough of a protein called hemoglobin. Hemoglobin helps carry oxygen in your blood. This can lead to anemia, which means feeling tired and weak.

Condition

What people with beta-Thalassemia report

Every report comes from a Lived member, sent anonymously.

Have you tried Blood transfusion therapy for beta-Thalassemia?

NameHow it went

About beta-Thalassemia

What It Is

Beta thalassemia is an inherited blood disorder in which the body makes too little hemoglobin, the iron-containing protein that lets red blood cells carry oxygen. Hemoglobin is built from two kinds of protein chains, alpha and beta. In beta thalassemia, the beta chains are reduced or missing, so red blood cells form poorly and many are destroyed early. The result is anemia, a shortage of healthy red blood cells, which can cause tiredness, weakness, shortness of breath and pale skin. How much this matters depends on the form. People with thalassemia minor (also called beta thalassemia trait) are carriers: they usually feel well and have, at most, mild anemia. Thalassemia intermedia causes mild to moderate anemia that may appear in early childhood or later, and it can bring bone changes, gallstones and a higher risk of blood clots. Thalassemia major, also known as Cooley's anemia, is the severe form. Babies usually develop serious anemia between 6 and 24 months of age, with poor growth, jaundice (yellowing of the skin and eyes) and an enlarged spleen and liver, and they need regular blood transfusions for life. Care teams often group the forms instead by whether regular transfusions are needed, calling them transfusion-dependent or non-transfusion-dependent thalassemia, and the newer treatments are approved on that basis.

Causes & Risk Factors

Beta thalassemia is caused by variants (changes) in the HBB gene, which holds the instructions for making beta-globin. Everyone has two copies of this gene, one from each parent. A person with one altered copy is a carrier with thalassemia minor. A person with two altered copies has thalassemia intermedia or major. When both parents are carriers, each pregnancy has a 1 in 4 chance of a child with thalassemia, a 1 in 2 chance of a carrier and a 1 in 4 chance of a child with neither. The condition is most common in families with roots in the Mediterranean, North Africa, the Middle East, India, Central and Southeast Asia, though it occurs in people of any background. It is not caused by anything a person or parent did, and it cannot be caught. Within families, the specific gene changes and other inherited factors help explain why two people with the same diagnosis can be affected very differently.

How It's Diagnosed

Thalassemia often first shows up on a routine complete blood count (CBC), a test that measures hemoglobin and red blood cells. The typical pattern is red cells that are smaller and paler than normal, sometimes with a low hemoglobin level. Because iron deficiency produces a similar picture, an important step is checking iron levels. In a carrier, the small red cells are not caused by a lack of iron and do not need treatment, and taking iron in that situation does not fix the numbers. A hemoglobin analysis (such as hemoglobin electrophoresis) then measures the different types of hemoglobin in the blood. In beta thalassemia, the normal adult type, hemoglobin A, is reduced or absent, while a minor type called hemoglobin A2, and often fetal hemoglobin (hemoglobin F), are raised. Genetic testing of the HBB gene confirms the exact variants, which helps predict severity, is the main test in babies under a year old, and allows testing of relatives. Severe forms may be picked up by newborn screening, and carrier testing before or during pregnancy lets couples understand the chance of having an affected child.

Treatment Options

Treatment depends on the form. Carriers generally need none. People with thalassemia intermedia may need folic acid, occasional transfusions during illness, surgery or pregnancy, and sometimes hydroxyurea, an oral medicine that boosts fetal hemoglobin. Fetal hemoglobin, the type made before birth, is built without beta chains, so raising it can partly make up for the shortfall. Removing the spleen (splenectomy) can ease anemia in some people with milder disease, but it leaves a lifelong higher risk of serious infection. For thalassemia major, regular red blood cell transfusions, usually every 3 to 4 weeks, are the foundation of care. They correct the anemia and allow normal growth and development. Each transfusion also adds iron the body cannot get rid of on its own, and over years this iron overload can damage the heart, liver and hormone-producing glands. Iron chelation therapy removes the excess. Deferasirox is a once-daily pill, deferiprone is a pill or liquid that requires regular blood counts because it can lower infection-fighting white cells, and a fever while taking it should be reported right away, and deferoxamine is given slowly under the skin, often overnight with a small pump. People with intermedia can also build up iron from absorbing extra iron from food, so they may need chelation too. For the same reason, iron supplements should be avoided unless a hematologist recommends them. Two newer medicines can lower how much blood a person needs. Luspatercept (Reblozyl), an injection every 3 weeks for adults who need regular transfusions, reduced transfusion needs by at least a third in about 1 in 5 people in its main trial, compared with about 1 in 20 on placebo; it carries a higher risk of blood clots and can raise blood pressure. Mitapivat (Aqvesme), a pill for adults with thalassemia whether or not they are transfused, is a pyruvate kinase activator, a drug that supports the energy supply of red blood cells. It can cause serious liver injury, so it is prescribed only through a restricted program with regular liver blood tests. A stem cell (bone marrow) transplant from a well-matched donor is the established cure and works best in children, but few people have a suitable donor and the procedure carries serious risks. Gene therapies now offer another route to stopping transfusions for people who need them regularly. Betibeglogene autotemcel (Zynteglo) adds a working beta-globin gene to a person's own stem cells, and exagamglogene autotemcel (Casgevy), approved from age 2, uses gene editing on the person's own stem cells. In trials most treated people stopped needing transfusions. Both require collecting the person's own stem cells, high-dose chemotherapy to clear the bone marrow before the treated cells are returned, and the chemotherapy commonly causes infertility, so fertility preservation is discussed beforehand.

What to Expect

Thalassemia minor does not usually affect health or life expectancy. Its main significance is for family planning, since a carrier whose partner is also a carrier could have a child with a serious form. Thalassemia major is a lifelong condition that shapes daily routines: a hospital or clinic visit every few weeks for a transfusion that takes a few hours, daily or near-daily chelation, and regular checks. Monitoring usually includes iron levels and liver tests every few months, yearly checks of the heart, hormones, eyes and hearing, and magnetic resonance imaging (MRI) scans that measure iron in the heart and liver. Delayed puberty, diabetes, thyroid problems, weak bones, gallstones and heart rhythm problems are among the complications this monitoring is designed to catch early. Outlook has improved greatly. Severe thalassemia was once often fatal by early adulthood, while people treated well today commonly live into their 50s, 60s and beyond, with work, study and families of their own. Keeping up with chelation is central to protecting the heart and liver, and its daily demands are one of the harder parts of living with the condition. Thalassemia intermedia varies more. Some people stay well with occasional transfusions, while others gradually develop iron buildup, blood clots, bone problems or leg ulcers and need more treatment over time. Pregnancy is possible with planning, but it often requires more transfusions and changes to chelation, so it is best arranged with the specialist team ahead of time. Care is usually coordinated by a hematology or thalassemia center, and children need a planned move to adult care.

When to Seek Help

Ask about testing if routine blood work shows small red blood cells without iron deficiency, if a relative has thalassemia or is a carrier, or before or early in a pregnancy if you have family roots in a region where the trait is common. A baby or young child who becomes pale, feeds poorly, grows slowly or develops a swollen belly should be checked by a clinician. Contact your care team promptly if anemia symptoms such as tiredness or breathlessness are clearly worse between transfusions, or if you notice yellowing of the skin or eyes (which can point to gallstones or liver strain), a swollen or painful leg (a possible blood clot), or new heart palpitations (a possible sign of iron affecting the heart). Some problems need urgent care. Sudden chest pain or sudden shortness of breath can mean a clot has reached the lungs and needs emergency care. If your spleen has been removed, treat a fever of 38°C (100.4°F) or higher, chills or feeling suddenly unwell as urgent: contact your care team right away, take any standby antibiotic they have given you, and go to emergency care if you cannot be seen promptly, because infection can become life-threatening within hours without a spleen.

Questions to Ask Your Doctor

  1. 1.Which form of beta thalassemia do I or my child have, and what does that mean for treatment over the coming years?
  2. 2.How will we measure iron buildup, and which chelation option fits our routine and side effect concerns?
  3. 3.Is a stem cell transplant or gene therapy realistic for us, and what are the trade-offs, including fertility?
  4. 4.Should my partner or other family members have carrier testing before we plan a pregnancy?
  5. 5.Which specialists should be part of the care team, and how often will we see each of them?

Last reviewed • Oct 2026

Educational content, not medical advice.